Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Cancer. 2021 Dec 7;128(6):1206–1218. doi: 10.1002/cncr.34025

Figure 2.

Figure 2.

Top: Progression-free survival (PFS). A total of 12 PFS events were observed during 475.7 person-months. Left: Among all patients, median PFS was 23.5 months (95% CI 10.7-not reached [NR]); at 1 and 3 years, 66% and 46% remained progression-free. Right: At 1 and 3 years, 100% of Lynch-like patients remained progression-free; among methylated patients, only 55.6% and 30% were progression-free (p=0.02). Median PFS within the methylated cohort was 14.6 months (95% CI 7.8-NR). Bottom: Overall survival (OS). Left: Among all patients, median OS was 40 months (95% CI 25.3-NR); at 1 and 3 years, overall survival proportions were 91% and 56%. Right: Among methylated patients, median OS was 31.0 months (95% CI 24.9-NR) and overall survival proportions at 1 and 3 years were 88.6% and 43.1% (p=0.04). All Lynch-like patients remained alive at those timepoints.